Cobra Biologics and KAHR Medical Extend Their Partnership
News Jun 26, 2012
Cobra Biologics and KAHR Medical Limited have announced a continuation of their partnership.
The partnership will allow Cobra Biologics to advance both KAHR-101 and KAHR -102 for future pre-clinical and clinical testing using Cobra Biologic’s maxXpress service which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team, to enable rapid clone selection and production.
Cobra Biologics will also be carrying out the process development and scale up for the GMP production of both KAHR-101 and KAHR-102.
Peter Coleman, CEO at Cobra Biologics, said: “I am delighted to extend our partnership with KAHR which has been strengthened over a number of years due to the excellent working relationship between both technical teams and we look forward to its continuation.”
Dr Noam Shani, CEO of KAHR Medical, said: “It has been a pleasure working with Cobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of both KAHR-101 and KAHR-102.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE